OptimizeRx (NASDAQ:OPRX) Given Market Outperform Rating at JMP Securities

JMP Securities reissued their market outperform rating on shares of OptimizeRx (NASDAQ:OPRX – Free Report) in a research report released on Tuesday, Benzinga reports. JMP Securities currently has a $15.00 target price on the stock. Several other brokerages have also commented on OPRX. Stifel Nicolaus restated a buy rating and set a $13.00 target price […]

Related Keywords

Canada ,Hong Kong ,Stifel Nicolaus ,Optimizerx Company Profile ,Royal Bank ,Optimizerx Corporation ,Barclays ,Charles Schwab Investment Management Inc ,Nuveen Asset Management ,Hong Kong Ltd ,Thrivent Financial For Lutherans ,Nasdaq ,Free Report ,Moderate Buy ,Asset Management ,Financial Advisors ,Schwab Investment Management ,Kong Ltd ,Get Free Report ,Evidence Based Physician Engagement ,Care Banner ,Optimizerx Daily ,Optimizerx ,Nasdaq Oprx ,Oprx ,Computer And Technology ,Reiterated Rating ,Jmp Securities ,